125 filings
Page 5 of 7
8-K/A
x5bnndpbwmpi7rj55
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
0o6stx c2z3
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
072jfwue7cw7mnm3pv
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
xd1qysdze
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
nosc6f7wwd1k
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
o8fvv24
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
io8ka6 n9
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
0ai3 m9ylidc61uoogd
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
zg9aqvs5y 52zw0
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
h8so8rtvahrxjionx
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
ujlboes7 bs8
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
925fbdqaen
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
mqs457xzrm29an2cei
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
10-Q
t38vvmf
20 Sep 21
Quarterly report
4:17pm
8-K
6421ufmxtu3r1 rysic
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
tly9ra
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
S-8
mosilo
23 Aug 21
Registration of securities for employees
4:35pm
SEC STAFF
34xs37
13 Aug 21
SEC staff action: Order
12:00am
8-K
cj9 cwxbf
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
5:26pm